EUVIMEDEUVIMED entdecken
Open Access

Use of medications associated with weight change among participants in the All of Us research programme

Erik Almazan iD, Jessica L Schwartz, Kimberly A Gudzune iD

Clinical Obesity · 2023-10 · 13 (5)

DOI: 10.1111/cob.12609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Obesity, online erschienen am 16.07.2023. Verfasst von Erik Almazan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Population Health, Anti-Obesity Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our objective was to describe the use of medications associated with weight change among US adults with overweight/obesity, including anti‐obesity medications (AOMs), weight‐loss‐promoting and weight‐gain‐promoting medications. We performed a cross‐sectional analysis of data from the nationwide All of Us Research Programme. We included adults with measured body mass index (BMI) ≥ 27 kg/m 2 enrolled between 2018 and 2022 across the United States. We used linked electronic health record data to determine medication use ±12 months of BMI measure. Our 132 057 participants had mean age 54 years and mean BMI 34 kg/m 2 ; 60% of participants were women, 62% White, and 32% Black. Only 1% used any AOM, and 14% used at least one weight‐loss‐promoting medication. We found that 36% used at least one weight‐gain‐promoting medication, and approximately 20% used multiple weight‐gain‐promoting medications. While AOMs are underutilized by participants with overweight/obesity, weight‐gain‐promoting medication use is common. Our results raise concern about potential iatrogenic weight gain from medications. Future research is needed to estimate the long‐term effect of weight‐gain‐promoting medications on weight status and determine whether weight‐loss benefits occur with their discontinuation. Clinician education on AOMs and weight‐loss‐promoting medications may be needed to increase their use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Population HealthAnti-Obesity AgentsAdultHumansFemaleUnited StatesMiddle AgedMaleOverweightCross-Sectional StudiesObesityBody Mass IndexWeight Gain

Stichwörter der Autor:innen

anti-obesity agentsbody weight changesdrug side effectsobesity

Substanzen

Anti-Obesity Agents

Autor:innen und Institutionen

  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Health Policy & Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Johns Hopkins Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, Maryland, USA.

ORCID-Profile: Erik Almazan, Kimberly A Gudzune

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • NIMH NIH HHS
  • NIA NIH HHS
  • ODCDC CDC HHS
  • National Heart, Lung, and Blood Institute
  • National Institute of Mental Health

Zitieren

APA

Almazan, E., Schwartz, J. L., & Gudzune, K. A. (2023). Use of medications associated with weight change among participants in the All of Us research programme. Clinical Obesity, 13(5). https://doi.org/10.1111/cob.12609

Vancouver

Almazan E, Schwartz JL, Gudzune KA. Use of medications associated with weight change among participants in the All of Us research programme. Clinical Obesity. 2023;13(5). doi:10.1111/cob.12609

BibTeX
@article{Almazan2023,
  author = {Almazan, Erik and Schwartz, Jessica L and Gudzune, Kimberly A},
  title = {Use of medications associated with weight change among participants in the All of Us research programme},
  journal = {Clinical Obesity},
  year = {2023},
  volume = {13},
  number = {5},
  doi = {10.1111/cob.12609}
}
Kostenlos starten →